<?xml version="1.0" encoding="UTF-8"?>
<fig id="f4-1030717" position="float">
 <label>Figure 4.</label>
 <caption>
  <p>Comparative analysis of serum cytokine production in tocilizumab-treated 
   <italic>versus</italic> patients that received Tac/MTX only. Concentration of IL-6, sIL-6R, IL-2, IL-4, IL-10, IL-17, IFN-γ, and TNF-α in the serum of patients that were treated with Toc/Tac/MTX (●, n=35) or Tac/MTX (control) (○, n=11) for the prevention of aGvHD prior to the start of conditioning and at days 7, 14 and 28. *
   <italic>P</italic>&lt;0.05, **
   <italic>P</italic>&lt;0.01, ***
   <italic>P</italic>&lt;0.001. IL: interleukin; sIL: soluble interleukin; TNF-α: tumor necrosis factor α; IFN-γ: interferon γ.
  </p>
 </caption>
 <graphic xlink:href="103717.fig4" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
